Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
| ▸ | GRK6 | P43250 | 2/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 8/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451506 | 0.91 | CYP19A1 (0.54) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6450451 | 0.87 | NPC1 (0.56) | IDH1GRK6NOTUMNPC1MEN1 | |
| SCHEMBL6456324 | 0.85 | GAA (0.50) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6450529 | 0.84 | GRK6 (0.46) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6454364 | 0.82 | MAPT (0.51) | GAAMEN1KMT2ARAB9AMAPT | |
| SCHEMBL6449893 | 0.81 | MAPT (0.43) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6450064 | 0.81 | GRK6 (0.47) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6461158 | 0.81 | GRK6 (0.45) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6449669 | 0.80 | MGAM (0.49) | IDH1GRK6NOTUMMGAMGAA | |
| SCHEMBL6448635 | 0.79 | SMN1; SMN2 (0.55) | GRK6MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | IDH1 89/4885GRK6 2654/4885NOTUM 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.